Abstract
Syphilis is an important global health threat and little has changed in its treatment since the mid-20th century. For late-latent or syphilis infection of unknown duration, the standard treatment of multiple intramuscular injections of benzathine penicillin G (BPG) are associated with significant pain and distress to clients and caregivers, negatively impacting on treatment completion. Based on pharmacokinetic modelling from a Phase I study of subcutaneous infusion of high dose BPG (SCIP), we present its feasibility, safety and tolerability for treatment of syphilis in a single infusion. SCIP leads to more sustained penicillin concentrations above the desired target with less reported pain and reduced clinic visits.
Reference10 articles.
1. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.;Bull World Health Organ,2019
2. World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022.
3. Department of Health. Fifth National Aboriginal and Torres Strait Islander blood borne viruses and sexually transmissible infections strategy 2018-2022. Commonwealth of Australia; 2018.
4. Inoculation syphilis in human volunteers.;Medicine,1956
5. Treatment completion with three-dose series of benzathine penicillin among people diagnosed with late latent and unknown duration syphilis, Maricopa County, Arizona.;Sex Transm Dis,2023